FDA Approves 1st Immunotherapy Breast Cancer Drug
The combination of immunotherapy (Tecentriq) and chemotherapy (Abraxane) received accelerated approval for triple-negative breast cancer that is locally advanced or has spread, cannot be surgically removed, and has cells that have a protein called PD-L1, CNN reported.
Source: WebMD Health - Category: Consumer Health News Source Type: news
More News: Abraxane | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Health | Immunotherapy